<DOC>
	<DOC>NCT00836927</DOC>
	<brief_summary>To describe the long-term safety of deforolimus in patients for whom a clinical benefit has been established in a prior parent trial with deforolimus and/or in those who remain in long-term follow-up.</brief_summary>
	<brief_title>Extension Trial of Deforolimus in Patients With Advanced Cancer (8669-038)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must have participated on a deforolimus parent trial Patients must have derived a clinical benefit from the parent trial Patient is not on any other anticancer treatment(s) unless the therapy was allowed on the parent protocol ECOG performance status less than or equal to 2 if the patient is scheduled to receive treatment with deforolimus; no requirement if the patient is included for followup purposes only Patients of childbearing potential must have a negative pregnancy test within 7 days prior to screening and must use approved contraceptive from screening until 30 days after the last dose of study drug Signed informed consent Has not participated on a parent trial Women who are to receive study drug who are pregnant or lactating Any condition in the Investigator's judgment that renders the patient unable to fully understand and provide informed consent and/or comply with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>